CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 40 enrolled
Drug / intervention
Ramipril 10 mg capsule +1 moredrug
Likely dose
Ramipril 10 mg capsulefrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00829452
NCT00829452Phase 1Completed

Randomized, 2-Way Crossover Bioequivalence Study of Ramipril 10 mg Capsule and Altace® Administered as the Content of 1 x 10 mg Capsule Mixed With Applesauce in Healthy Subjects Under Fasting Conditions.

Teva Pharmaceuticals USA·interventional·Posted Jan 27, 2009·Updated Aug 19, 2024

In Brief

A Phase 1 clinical trial evaluating Ramipril 10 mg capsule and Altace® 10 mg capsule for Healthy. Completed, enrolled 40 participants across 2 sites.

Detailed Summary

The objective of this study is to compare the rate and extent of absorption of Ramipril 10 mg capsule (test) versus Altace® (reference) administered as the content of 1 x 10 mg capsule mixed with applesauce under fasting conditions.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesCanada
Collaborators--

Timeline

Phase 1CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 27, 2009
Enrollment StartAug 1, 2004
Primary CompletionOct 1, 2004
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 17.4 years ago

Interventions

Ramipril 10 mg capsuledrug

1 x 10 mg

Altace® 10 mg capsuledrug

1 x 10 mg